Thus, dominant clonal TET2 mutations—particularly when co-occurring with ASXL1—may delineate a biologically aggressive subgroup that shares key pathophysiologic features with secondary AML despite fulfilling strict diagnostic criteria for de novo disease. The gene discussed is TET2; the disease is acute myeloid leukemia.